A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. 75-79”
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
(1994) · Medical Entomology and Zoology · Cited by 4,156
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P. D., & Johanson, J. F. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,080
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 584
Stewart, W. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00701-7 · Cited by 492
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
The Health-Related Quality of Life and Economic Burden of Constipation
Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., & Coyne, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00006 · Cited by 396
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
- 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
- Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43
Cited by
Items 401–500 of 581
Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction
Camilleri, M., Sarnelli, G., Andresen, V., Meerveld, B. G., Howden, C. W., Izzo, A. A., & Jones, K. L. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.02.010 · Cited by 4
Self-citationGoyal, O., Goyal, M. K., Singh, B., Singh, A., Goyal, P., Mehta, V., Kaushal, S., & Sood, A. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70828 · Cited by 3
Magen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_30 · Cited by 3
Burst-patterned stimulation restores colonic motility in preclinical models
Barth, B. B., & Grill, W. M. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu4615 · Cited by 3
Song, H. Y., Jung, S.-W., & Kim, Y. S. (2022) · The Korean Journal of Helicobacter and Upper Gastrointestinal Research · doi:10.7704/kjhugr.2022.0011 · Cited by 3
“Summary of the Clinical Trials of Prucalopride Study Subject Design Country Comparison Number Outcome Camilleri et al.82 (2008) CC Multi-center, DBPC USA Placebo vs. prucalopride 2 mg vs. 4 mg q.d., 12 weeks 209:207 :204 ≥3 SCBM/wk 12.0%:30.9%:28.4% Quigley et al.8383 (2009) CC Multi-center, DBPC USA Placebo vs. pruca…”
InfluentialUtilisation des médicaments prokinétiques en réanimation : indications et limites ?
Libert, N., de Rudnicki, S., Cirodde, A., Janvier, F., Leclerc, T., Borne, M., & Brinquin, L. (2009) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2009.08.008 · Cited by 4
“[78] Camilleri M, Kerstens R, Rykx A, Vandeplassche L.”
Enteric Neuromuscular Pathology Update
Knowles, C. H., & Martin, J. E. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.09.007 · Cited by 3
Wang, H., Lane, K. E., Lou, Z., Parker, S. E., & Placke, M. E. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104586 · Cited by 3
Effectiveness and safety of acupuncture in the treatment of chronic severe functional constipation
Zhu, D., Hu, J., Chi, Z., Ouyang, X., Xu, W., Luo, Z., Cheng, C., Wu, J., Chen, R., & Jiao, L. (2021) · Medicine · doi:10.1097/md.0000000000024589 · Cited by 3
“stool is hard, often tense and feels incompletely evacuated.([2]) According to epidemiological studies found that the global prevalence of chronic idiopathic constipation is about 16%, affecting about 17.”
BackgroundChen, S., Liu, L., Li, Y., Li, H., Sun, X., Zhu, D., Meng, Q., Yao, S., & Du, S. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1856919 · Cited by 3
Constipation in a 40-year-old woman
Panda, H., & Andrews, C. N. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.150761 · Cited by 3
A Case-Based Approach to Constipation in Primary Care
Snell, D. B., Faruqui, S., & Bosworth, B. P. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.08.015 · Cited by 3
The multidimensional clinical profile for disorders of gut-brain interaction
Iyengar, P., & Chang, L. (2024) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.23000008 · Cited by 3
The use of prucalopride in real life for the treatment of constipation subtypes: ups and downs
Bassotti, G., & Bellini, M. (2013) · Techniques in Coloproctology · doi:10.1007/s10151-013-1026-7 · Cited by 3
Magen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_33 · Cited by 2
Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Song, K. H., Cho, Y. S., Shin, J. E., Jung, H., Park, S., Kang, S. J., Kim, J., Lee, Y. J., Lim, H. C., Park, H. S., et al. (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.156 · Cited by 2
DHYANESH, R., SHREE, N., I., J., ALBERT, K. S., M., S. S., & S., V. P. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i2.56700 · Cited by 2
Newer agents for constipation: prucalopride
Müller-Lissner, S. A. (2013) · doi:10.2217/ebo.12.372 · Cited by 2
Yeon, S.-E., Kim, S. Y., Chung, W. C., Jeon, S. W., Park, S. J., Choi, C. H., & Choi, M. (2021) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.099 · Cited by 2
Volodikhina, A. A., Akhmedova, A. R., Uzdenov, M. B., Dzhabrailova, M. L., Voytleva, R. K., & Achilov, V. I. (2022) · Pharmacophore · doi:10.51847/lrj9rea6ft · Cited by 2
Yang, J., Guo, J., Yang, X., Chen, J., Bai, T., & Liu, S. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14708 · Cited by 3
Xiong, Z., Ma, P., Zhang, H., Liu, C., Liu, B., Liu, Z., & Yan, S. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14770 · Cited by 3
The Diagnostic Yield of Laboratory Tests in Chronic Constipation in Adults
Ramadhan, A., Mustafa, A., ISSA, R. S., & Hassan, A. B. (2024) · Cureus · doi:10.7759/cureus.66116 · Cited by 2
“The distinction between these is based on radio-opaque marker study and anorectal manometry [4,5].”
BackgroundDo Most Children with Functional Constipation Meet the Commonly Used Clinical Trial Endpoints?
Arrizabalo, S., Benítez, C. A. V., Velasco‐Suárez, D. A., Giner, R., & Saps, M. (2025) · Children · doi:10.3390/children12020234 · Cited by 2
Controversias en Síndrome de Intestino Irritable
Silva, A. M., & Landskron, G. (2010) · Universidad de Chile · Cited by 3
Keller, J., & Layer, P. (2012) · Viszeralmedizin · doi:10.1159/000341992 · Cited by 2
Komada, T., Matsuura, T., Mikami, T., Suzuki, K., Sugimoto, H., Kimura, N., Ohmi, T., Toga, T., Nakai, Y., & Eda, H. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.013 · Cited by 2
Management of Nonmotor Symptoms of Parkinson's Disease
Gálvez-Jiménez, N., Fernandez, H. H., Espay, A. J., & Fox, S. H. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.010 · Cited by 2
Chen, Z., Tan, M., Shan, C., Yuan, X., Chen, L., Shi, J., Lan, Y., & Li, Y. (2022) · Angewandte Chemie · doi:10.1002/ange.202212160 · Cited by 2
Drugs Acting on the Gut: Prokinetics, Antispasmodics, Laxatives
Har, A. F., & Croffie, J. M. B. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-709-9_41 · Cited by 2
Constipation Treatment in Neurological Disorders
Gallelli, L., Pirritano, D., Palleria, C., & Sarro, D. (2012) · InTech eBooks · doi:10.5772/29813 · Cited by 2
“It enhances colonic transit in healthy control subjects and in patients with chronic constipation, in a dosedependent way (Bouras et al., 1999; Bouras et al., 2001; Camilleri et al., 2008; De Maeyer et al., 2008).”
BackgroundDried plums (prunes) for the treatment of constipation
Scott, S. M., & Knowles, C. H. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.82 · Cited by 2
“This pragmatic approach broadened inclusion beyond the parameters used for many clinical trials of new drugs for chronic constipation, in which patients from secondary and tertiary care, most of whom have failed treatment with laxatives, are selected on the basis of a long symptom duration (6 months) and marked bowel…”
BackgroundLayer, P. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.820049 · Cited by 2
Existing and emerging therapies for irritable bowel syndrome
Acosta, R. D., & Cash, B. D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.566214 · Cited by 2
“In three Phase III RCTs of prucalopride in patients with severe chronic constipation, the prucalopride-treated groups (2 mg/day and 4 mg/day) experienced significantly improved bowel function and reduced severity of symptoms compared to placebo [65-67].”
BackgroundGastrointestinal Dysfunctions in Parkinson’s Disease
Kim, J., & Sung, H. Y. (2015) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2015.4.1 · Cited by 2
“위장운동촉진제인 5-HT4효능제 중 최근 개발 된 procalupride는 여성의 만성적이고 약물불응변비에 강력한 효능이 입증되어 파킨슨병 환자에서 사용을 권유할 만하다.(45)”
Nowe leki w zaburzeniach czynnościowych przewodu pokarmowego
Bartnik, W. (2010) · Via Medica Journals · Cited by 2
Small Intestinal Bacterial Overgrowth in Patients with Systemic Sclerosis
Rawn, S. M., Pittman, N., BEATTIE, K. A., Bazzaz, A. H. Z., & LARCHÉ, M. J. (2017) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.219077 · Cited by 2
“[25,28-30] [18]”
Efficacy and safety of prucalopride in the treatment of chronic constipation
Kanaki, A. R., Kanaki, A. A., & Singanal, S. (2018) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20181649 · Cited by 2
Mousa, H. M., Barsamian, J. M., Benitez, A., Webster, J., & Fiorino, K. N. (2020) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-020-00199-z · Cited by 2
Hu, W., Ying, X., Sun, J., Fan, B.-H., & Guo, R. (2021) · Medicine · doi:10.1097/md.0000000000026349 · Cited by 2
Videlock, E. J., & Chang, L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch75 · Cited by 2
Dysmotility of the Small Intestine and Colon
Szarka, L. A. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch61 · Cited by 3
Dharmarajan, T. S., Widjaja, D., & Pitchumoni, C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_45 · Cited by 2
Magen-Darm-Mittel und Laxantien
Mössner, J. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_32 · Cited by 3
Magen-Darm-Mittel und Laxantien
Mössner, J. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_32 · Cited by 2
Drugs Acting on the Gut: Prokinetics, Antispasmodics, Laxatives
Har, A. F., & Croffie, J. M. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-43268-7_44 · Cited by 2
Fricke, U., & Schwabe, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_2 · Cited by 2
The Management of Constipation
Maslekar, S. K., & Jayne, D. G. (2011) · Springer eBooks · doi:10.1007/978-0-85729-889-8_27 · Cited by 2
Constipation and Constipation Syndromes
Bharucha, A. E., & Grover, M. (2012) · Wiley eBooks · doi:10.1002/9781118321386.ch61 · Cited by 2
Defining a responder in treatment trials for chronic idiopathic constipation
Raja, S., & Ford, A. C. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04504.x · Cited by 2
Piessevaux, H. H., Camilleri, M., Yiannakou, Y., Tack, J. F., Quigley, E. M. M., Sanchez, S. D. S., Kerstens, R., & Levine, A. (2015) · Gastroenterology · doi:10.1016/s0016-5085(15)31028-3 · Cited by 2
Self-citationJones, O. M. (2016) · Wiley eBooks · doi:10.1002/9781118674680.part3 · Cited by 2
Managing functional constipation: the course doesn’t always run smooth
Fenton, C., & Kang, C. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00803-0 · Cited by 2
Stefano, M. D. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002985 · Cited by 1
Update on the Treatment of Autonomic Disorders
Eid, A. M., Vázquez-Vélez, G. E., Maliszewski, B., Butler, M., Bucelli, R. C., Perlmutter, J. S., & Luca, D. G. D. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-025-00830-0 · Cited by 1
Łabuda, M., Bogucka, A., Mentel, O., Sowińska, T., Szema, A., Sikora, J., Słojewska, A., Kotkowiak, A., Królikowska, K., & Knychalska, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.81.59982 · Cited by 1
“A placebo-controlled trial involving 620 individuals demonstrated that prucalopride remarkably improved intestinal function and reduced the severity of symptoms with serious chronic constipation [8].”
Exploring a microbiota-targeted dietary strategy for irritable bowel syndrome
Dou, W., Zhang, C., Shentu, J., He, H., Yu, L., Tian, F., Zhao, J., Chen, W., Yu, Z., & Zhai, Q. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106758 · Cited by 1
Defining a responder in treatment trials for chronic idiopathic constipation: authors’ reply
Mangel, A. W., Johanson, J. F., Li, Y., Kersey, K., & Daniels, O. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04518.x · Cited by 1
Neue Medikamente zur Behandlung der Obstipation
Adam, B., Liebregts, T., & Gerken, G. (2010) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-010-1081-z · Cited by 1
“Es traten jedoch keine kardiovaskulären Nebenwirkungen auf [15, 16].”
BackgroundHong, S. N., Shin, J. E., Hong, K. S., Jung, K. W., Lee, T. H., Lee, B. E., Park, S., Kim, S., Park, K. S., & Choi, S. C. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.1.9 · Cited by 1
“적 무작위 대조 연구에서 잘 입증되었다[11-13].”
The Advantages and Disadvantages of Prokinetics
Seo, J., & Jung, K. W. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.478 · Cited by 1
“이에 프루칼 로프리드는 중증도의 만성 변비 환자군을 대상으로 주로 연 구가 이루어졌으며, 변비와 관련된 증상과 삶의 질, 환자 만 족도에서 유의한 호전을 보여준 바 있다[38-40].”
Gastrointestinal and Swallowing Disturbances in Parkinson's Disease
Pfeiffer, R. F. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch24 · Cited by 3
Core Aspects of Clinical Development and Trials in Chronic Idiopathic Constipation
Harris, M. S., & Tangphao, O. (2012) · InTech eBooks · doi:10.5772/28002 · Cited by 1
“A total of 2717 patients with chronic constipation were treated in placebo-controlled, double-blind, Phase 2 and Phase 3 trials (Miner et al., 1999; Emmanuel et al., 2002; Coremans et al., 2003; Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009; Müeller-Lissner et al., 2009).”
BackgroundMethodInfluentialKeeping things Moving: Preventing and Managing Constipation
Gandell, D., & Alibhai, S. M. H. (2010) · Wiley eBooks · doi:10.1002/9781118281796.ch11 · Cited by 1
Irritable Bowel Syndrome with Constipation
Everhart, K. K., & Lacy, B. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0332-0_4 · Cited by 1
Guías de diagnóstico y tratamiento del estreñimiento en México. C) Tratamiento médico y quirúrgico
Remes-Troche, J. M., Escudero, O. G., Chávez, M. E. I., Lugo, A. N., López‐Colombo, A., Bielsa, M. V., & Guindic, L. C. (2011) · Revista Portuguesa de Pneumologia · Cited by 4
Novel strategies and future landmarks in the treatment of irritable bowel syndrome
Róka, R., Gecse, K. B., & Wittmann, T. (2009) · Therapy · doi:10.2217/thy.09.22 · Cited by 1
Keller, J., Wedel, T., Seidl, H., Kreis, M. E., Andresen, V., & Medizin, A. I. (2011) · Cited by 1
Levine, S. K., & Shega, J. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-3796-7.00024-0 · Cited by 1
Management of patients with ‘refractory’ IBS: how to approach the patientMultiple choice questions
Athanasakos, E., & Emmanuel, A. V. (2013) · doi:10.2217/ebo.13.530 · Cited by 1
Sura, S. P., & Christie, J. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0332-0_3 · Cited by 1
Transient Neurogenic Bowel Dysfunction in a Case of Cocaine-Induced Spinal Cord Infarction
Nieto, L. M., Narvaez, S. I., Asthana, A., Mohammed, A., & Kinnucan, J. A. R. (2022) · Cureus · doi:10.7759/cureus.23834 · Cited by 1
“Another manifestation of SCI is autonomic dysfunction, causing symptoms that include sexual, bowel, and bladder dysfunction.”
BackgroundInfluentialMagen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_33 · Cited by 3
Knowles, C. H. (2017) · Springer eBooks · doi:10.1007/978-3-662-53210-2_10 · Cited by 1
What role for ▼prucalopride in constipation?: Table
(2011) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2011.02.0050 · Cited by 1
Wang, X., Sun, Y., Yan, S., Shi, H., Zhu, L., Gao, S., & Liu, Z. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04313-z · Cited by 1
“SCC is deeply associated with delay colonic motility and infrequent bowel movements [1, 24], especial in women [25].”
Dehury, S., Mohapatra, S., Das, H. S., Goutam, S., & Kaushik, C. (2023) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_530_22 · Cited by 1
“[12,14,22,24] Headache and diarrhea were mostly reported from the Prucalopride arm with the incidence of nausea, flatulence, and bloating side effects being equal in both groups.”
InfluentialCamilleri, M., & Ford, A. C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18527 · Cited by 1
“…pruca-lopride were almost equally effective at accelerating colonic transit at 48 h [17] supported the approval of 2 mg prucalopride as the recommended adult dose, given that the pivotal Phase 3 trial showed similar efficacy of the 2 and 4 mg doses for patient-reported symptom-based endpoints [36].”
Self-citationGastrointestinal Complications of Neuromuscular Disorders
Ismail, M. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00004-9 · Cited by 1
Melter, M., & Buderus, S. (2013) · Springer eBooks · doi:10.1007/978-3-642-24710-1_47 · Cited by 1
Bueno, L. P. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(09)71526-x · Cited by 1
Symptomatic Care Pending Diagnosis
(2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0738-6.00001-2 · Cited by 1
Varma, S., & Staller, K. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18219 · Cited by 1
Grobler, A. C. (2014) · ResearchSpace (University of KwaZulu-Natal)
Prucalopride for the treatment of chronic constipation
Rezaie, A. R., Cheng, E. J., Jijon, H. B., Kumar, S., & Storr, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009636
Stacy, M. A., & Jankovic, J. J. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch35
Törnblom, H., & Simrén, M. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch14
Constipation de transit : les traitements ayant fait la preuve de leur efficacité
Zeitoun, J., & de Parades, V. (2011) · Côlon & Rectum · doi:10.1007/s11725-011-0331-4
Gastro-intestinale aandoeningen
Mathus-Vliegen, E. M. H. (2013) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-9265-0_15
Ke, M., Zou, D., Yuan, Y., Li, Y., Li, L., Hao, J., Hou, X., & Kim, H. J. (2012) · Neurogastroenterology & Motility · doi:10.1111/nmo.12033
System evaluation of electro-acupuncture (EA) for functional constipation
Wang, Z.-Q. F., Wang, S., Fu, W., Liu, Z., & Cui, S. (2013) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2013.6732635
Handling of missing data in long‐term clinical trials: a case study
Janssens, M., Molenberghs, G., & Kerstens, R. (2012) · Pharmaceutical Statistics · doi:10.1002/pst.1532
Self-citationTreatment of Constipation – the Search Continues
(2008) · AAP Grand Rounds · doi:10.1542/gr.20-4-41
Do We Know How to Manage Irritable Bowel Syndrome
Emmanuel, A. V. (2014)
Funktionelle Magen-Darm-Erkrankungen
Keller, J., & Layer, P. (2013) · Der Internist · doi:10.1007/s00108-013-3379-4
EXERCICE N° 37 : Ça ressemble à du Prescrire, mais ce n'est pas du Prescrire
Frampton, J. E., & Zealand, N. (2016)
Clinical and economic profile of prucalopride in the treatment of chronic constipation in women
Stanghellini, V., & Eandi, M. (2012) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v13i3.271
“settimane) Camilleri, 2008 [57] -0,4 -0,7§ -0,7§”
BackgroundInfluentialJORNADA DE ACTUALIZACIÓN EN GASTROENTEROLOGÍA APLICADA
Mearin, F., Juan, A. P., & Balboa, A. (2016)
THÈSE POUR LE DIPLÔME D'ÉTAT DE
Médecine, D. E. (2007)
Funktionelle Magen-Darm-Erkrankungen: Was tun, wenn der Bauch streikt?
Keller, J., & Layer, P. (2014) · CME · doi:10.1007/s11298-014-1199-x
Metadata
- Authors
- Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Camilleri, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-29
- Volume
- 358
- Issue
- 22
- Pages
- 2344-2354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068454300
- Cited by
- 576
- References
- 36
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
- FWCI
- 45.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.